Javier Cortés
Institute of Breast Cancer, Quirón Group, Barcelona (Spain) · IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain · MedSIR
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Javier Cortés as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07619066 · A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.MedSIR · not yet recruiting · Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer, HER2 Mutation · principal investigator
- Ph3NCT06382948 · Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.MedSIR · recruiting · Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer · principal investigator
- Ph2NCT06172127 · PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerMedSIR · active not recruiting · HER2-positive Breast Cancer · principal investigator
- Ph2NCT05227131 · Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerMedSIR · withdrawn · Metastatic Breast Cancer, Advanced Breast Cancer, HER2-positive Breast Cancer · principal investigator
- N/ANCT05217381 · Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 StatusMedSIR · completed · Early Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer · principal investigator
- Ph1/Ph2NCT04826016 · POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast CancerMedSIR · withdrawn · Advanced Breast Cancer · principal investigator
- Ph2NCT04335305 · Checkpoint Blockade in COVID-19 PandemicMedSIR · terminated · COVID-19, Pneumonia, Viral · study chair
- N/ANCT04002154 · Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPVProcare Health Iberia S.L. · completed · Human Papilloma Virus Infection, Human Papilloma Virus, Cervix Lesion · study chair
- Ph2NCT03795012 · Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer PatientsMedSIR · terminated · Breast Cancer · principal investigator
- Ph2NCT03222856 · Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & TaxanesMedSIR · completed · Breast Cancer · principal investigator
- Ph1NCT02562378 · T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerMedSIR · completed · Breast Cancer · study director
- Ph2NCT01973660 · PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerSOLTI Breast Cancer Research Group · completed · Breast Cancer · study chair
- Ph2NCT01669252 · Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast CancerSOLTI Breast Cancer Research Group · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:40 UTC. The ranking covers the 200 most relevant of 649 PubMed records, and a shared surname and initials can bring in a namesake. All 649 on PubMed
- Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med · 20202,673 citationsRCR 117.0
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.N Engl J Med · 20121,975 citationsRCR 51.1
- Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.N Engl J Med · 20151,670 citationsRCR 50.9
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.N Engl J Med · 20201,653 citationsRCR 74.7
- 1,567 citationsRCR 65.6
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med · 20211,463 citationsRCR 83.1
- Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med · 20101,247 citationsRCR 28.0
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.N Engl J Med · 20191,106 citationsRCR 41.3
- 1,071 citationsRCR 71.6
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.N Engl J Med · 20221,056 citationsRCR 72.2